Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prevention of vision loss in neovascular age-related macular degeneration with bevacizumab vs ranibizumab in outpatient setting
2007-004721-23Phase 3Completed
- Sponsor
- Klinikum Bremen-Mitte
- Start
- Aug 2007
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of ranibizumab and bevacizumab in exudative macular degeneration (2 arms), sponsored by Klinikum Bremen-Mitte. Primary endpoints: Mean change from baseline in BCVA at month 12 and Mean change from baseline in BCVA at month 24. Started Aug 2007; status: completed.
02
Drugs
ranibizumabbevacizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2007-004721-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004721-23.